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Abstract
Background:  Macrophages sense microorganisms through activation of members of the Toll-like
receptor family, which initiate signals linked to transcription of many inflammation associated genes. In this
paper we examine whether the signal from Toll-like receptors [TLRs] is sustained for as long as the ligand
is present, and whether responses to different TLR agonists are additive.
Results: RAW264 macrophage cells were doubly-transfected with reporter genes in which the IL-12p40,
ELAM or IL-6 promoter controls firefly luciferase, and the human IL-1β  promoter drives renilla luciferase.
The resultant stable lines provide robust assays of macrophage activation by TLR stimuli including LPS
[TLR4], lipopeptide [TLR2], and bacterial DNA [TLR9], with each promoter demonstrating its own
intrinsic characteristics. With each of the promoters, luciferase activity was induced over an 8 hr period,
and thereafter reached a new steady state. Elevated expression required the continued presence of
agonist. Sustained responses to different classes of agonist were perfectly additive. This pattern was
confirmed by measuring inducible cytokine production in the same cells. While homodimerization of TLR4
mediates responses to LPS, TLR2 appears to require heterodimerization with another receptor such as
TLR6. Transient expression of constitutively active forms of TLR4 or TLR2 plus TLR6 stimulated IL-12
promoter activity. The effect of LPS, a TLR4 agonist, was additive with that of TLR2/6 but not TLR4, whilst
that of lipopeptide, a TLR2 agonist, was additive with TLR4 but not TLR2/6. Actions of bacterial DNA were
additive with either TLR4 or TLR2/6.
Conclusions: These findings indicate that maximal activation by any one TLR pathway does not preclude
further activation by another, suggesting that common downstream regulatory components are not
limiting. Upon exposure to a TLR agonist, macrophages enter a state of sustained activation in which they
continuously sense the presence of a microbial challenge.
Background
Mammalian macrophages respond to a wide range of mi-
crobial products with induction of genes required for
host defence. Amongst these genes is a suite of inducible
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cytokines, including IL-1, TNF-α , IL-6 and IL-12, which
are required for protective innate and acquired immuni-
ty but also mediate much of the pathology of disseminat-
ed infections including toxic shock [1]. The archetypal
macrophage activating bacterial product is lipopolysac-
charide (LPS) or endotoxin. An understanding of the
mechanism of action of LPS was greatly expedited by the
identification of the Toll-like receptor [TLR] family and
the parallels between recognition of bacterial stimuli in
mammals and drosophila. Mice with mutations in the
TLR4 gene are hypo-sensitive to LPS [2–4]. Activation of
TLR4 on the cell surface which requires coooperation
with at least two other surface proteins, CD14 and MD2
[5] leads to recruitment of adaptor proteins (MyD88,
IRAK, TRAF6) that ultimately couple the recognition of
the microbial product to activation of the transcription
factor complex NF-κ B [Reviewed in [6]]. Translocation
of this transcription factor complex in turn contributes
to activation of the promoters of many inducible genes in
macrophages [1]. Another member of the TLR family,
TLR2, is absolutely required for recognition of a range of
surface components of gram-positive organisms includ-
ing bacterial lipopeptides [7]. Apart from bacterial cell
wall components, macrophages are able to recognize and
respond to bacterial DNA or CpG-containing immunos-
timulatory oligonculeotides [8,9]. A recent paper indi-
cates that yet another member of Toll-like receptor
family, TLR9, is required for optimal recognition of im-
munostimulatory DNA [10]. The TLR2, TLR4 and TLR9
pathways apparently converge at the level of MyD88,
since macrophages from mice with a mutation in this
gene are defective in activation by either gram-negative
or gram-positive organisms or bacterial DNA [11,12].
One clinically-important feature of the mammalian re-
sponse to LPS is the induction of tolerance. An animal
exposed to a sub-lethal dose of LPS, or to a non-toxic
LPS, enters a refractory period during which it can resist
lethal LPS exposure. Several groups have attempted to
model the phenomenon of endotoxin tolerance in vitro
by studying the ability of macrophages exposed to LPS to
recognise a secondary stimulus [5,13–22]. In these mod-
els, some responses that are measured (e.g. activation of
transcription factor NF-κ B, TNF-α  mRNA production)
occur transiently after LPS addition. Whereas TNF-α
mRNA is induced transiently in response to LPS and
then rapidly degraded [23] and the protein product is
produced and secreted in a bolus from the stimulated
cells [24], other mRNAs are elevated for as long as LPS is
present, up to 48 hrs after LPS addition [23]. Such genes
could be induced by autocrine stimuli produced in the in-
itial phase of activation. Alternatively, LPS may act to
cause a change of "steady state", and TNF-α  induction
and other early response genes could be a feature of a
transition state that cannot be reactivated until the fully
active state is allowed to completely decay. In such a
model, the new steady state could have an intrinsic half-
life or it could be maintained by continued stimulation.
Explanations for tolerance in macrophages in vitro gen-
erally involve selective modulation or repression of some
component of the signalling cascade, ranging from the
putative LPS receptor TLR4, through IRAK and various
regulators of NF-κ B [[5,17] and references therein].
Many of the proposed mechanisms of tolerance would
imply cross-desensitisation of responses to other bacte-
rial products presumed to share the same pathway, a
phenomenon that has been reported between TLR2 and
TLR4 [25,26].
It is self-evident that if genes such as TNF-α  and c-fos are
induced transiently by LPS, there is a state that might be
called "tolerance" or "repression" in that the mRNA and
protein declines despite the continued presence of the
stimulus. The transitory nature of TNF-α  induction is
probably a consequence of induction of nucleases that
specifically degrade the mRNA [27]. Such a feedback
mechanism would clearly interfere with subsequent in-
duction by any stimulus for as long as the nuclease activ-
ity was retained. By contrast, where mRNAs continue to
increase and there is no evidence of feedback control,
there is no reason to expect any restriction on additive
signaling by different TLR agonists unless there is an in-
trinsic limit to the amount of mRNA that can be made or
common pathway components are limiting. There is no
obvious reason why it would be desirable for macrophag-
es to restrict their ability to recognise more than one
TLR-related challenge simultaneously, especially in
mixed infections. Based upon these considerations, we
hypothesised that genes that are induced in a sustained
manner by TLR agonists would not display any kind of
"tolerance" and that there would be significant advan-
tage to macrophages in being able to integrate multiple
signals that induce such genes.
To address this hypothesis, we have developed novel re-
porter gene systems. The firefly luciferase gene product
is very unstable in the macrophage cell line RAW264,
and stably-transfected cells have provided a sensitive in-
dicator of transient activation of κ B-dependent tran-
scription in these cells [28]. We examined the regulation
of promoters of the IL-1β , IL-6 and IL-12p40 genes as
well as the widely-used κ B-responsive gene, ELAM (E-
selectin) in stably-transfected RAW264 cells. We dem-
onstrate that sustained activation of the promoters of
these genes requires the continued presence of microbial
agonist and that signaling by one such agonist does not
preclude additional activation through a distinct Toll-
like receptor pathway. In the second part of the study, we
use constitutively active forms of TLRs to generate the
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again show that their actions are additive with those of
agents that act through other TLRs. Finally, we show that
primary macrophages can, indeed, respond to multiple
TLR stimuli with increased cytokine secretion. In over-
view, we conclude that macrophages sense microbial
challenges continuously and can respond to more than
one stimulus simultaneously.
Results
Generation and characterisation of stably transfected 
RAW264 cell lines with two integrated luciferase reporters
Previous studies examined a stable transfectant of the
cell line RAW264, in which the firefly luciferase gene di-
rected by the NF-κ B-dependent HIV-1-LTR was inte-
grated into the genome. This line provided a sensitive
indicator of response to LPS and to CpG DNA [8,28]. In-
duction of luciferase activity was transient, reaching a
peak after around 2 hrs and then declining rapidly to
control levels. The time course of luciferase activation
was consistent with transient induction of nuclear NF-
κ B activity [8,28] and TNF-α  mRNA [8,28] demonstrat-
ed previously using RAW264 cells cultured in similar
conditions. Although NF-κ B is strongly implicated in
regulated gene expression in macrophages, numerous
other transcription factors (i.e. PU.1, Ets-2, Sp1, Stat-1,
C/EBPβ , γ  or δ , IRF-1 etc [1,29]) are regulated or induced
in LPS-stimulated cells, so we decided to examine more
complex promoters that are not solely dependent upon
NF-κ B.
To examine genes that are induced at a transcriptional
level in RAW264 cells, we made a series of stable
RAW264 cell transfectants with cytokine promoters
driving luciferase. Stable transfection avoids the compli-
cation that derives from the ability of macrophages to
recognise and respond to plasmid DNA [8]. The inter-
leukin-1β  gene is of particular interest, because previous
reports indicate that "LPS tolerance" does not prevent
re-induction of this gene or of the interleukin 6 gene
[30,31]. We cloned the human interleukin-1 β  promoter
into a renilla luciferase plasmid, which allowed us to pro-
duce lines in which the IL-1β  induction response could
be measured simultaneously with other promoters that
may, or may not, exhibit tolerance.
RAW264 cells were contransfected by electroporation
with two separate reporters and after 2 weeks of selec-
tion in G418, several hundred foci of stable transfectants
were pooled for further study. Because of the known var-
iation between RAW264 subclones in terms of LPS-in-
ducible gene expression [23] we chose not to study single
cell clones. In a separate study, we have confirmed that
all clones derived from the pools used in this study ex-
press both the firefly and renilla luciferase genes at low
levels, but vary considerably in whether that activity is
inducible by LPS or other agonists [32]. The expression
of luciferase and responsiveness to microbial challenge
has been stable in the pools of transfectants for at least 2
months in continuous culture. To our knowledge, this is
the first example of the use of multiple reporter genes in
a stably-transfected macrophage line.
Time and dose response curves for activation of luciferase 
expression
Comparative time and dose response curve analysis were
performed for each of the pooled transfectant lines with
different combinations of promoters. Each promoter
controlling firefly luciferase behaved in a unique man-
ner, regardless of the presence of the IL-1 promoter-re-
nilla luciferase gene in all of the lines, whereas the IL-1
promoter regulation was remarkably consistent in inde-
pendent lines with different combinations of firefly luci-
ferase reporters.
The ELAM-1 promoter, used commonly as an indicator
of κ B-dependent transcription [33]. displayed the high-
est basal activity and inducibility. In our studies of the
HIV-1-LTR, we found that adherence to tissue culture
plastic was stimulatory [unpublished], so the transfected
RAW264 cells were plated in the evening and stimulated
the next morning after the cells were fully adherent. We
considered the possibility that overnight culture could
lead to accumulation of endogenous stimulatory or in-
hibitory cytokines, so we examined the effect of replacing
the medium. The outcome depended upon the reporter
gene. When cells were exposed to fresh medium, ELAM-
luciferase activity decreased transiently, then increased
continuously over a 12 hr incubation (this is not obvious
in Fig 1A, because of the much larger effect of added
LPS). Following addition of 100 ng/ml LPS to unwashed
cells, ELAM-luciferase was detectably elevated 2-fold af-
ter 30 mins, and continued to increase relative to un-
stimulated expression for up to 6–8 hrs, after which it
declined (Fig 1A). In cells provided with fresh medium,
the tail-off at 6–8 hrs did not occur, and luciferase activ-
ity was still increasing at 12 hrs. Hence, endogenous reg-
ulators appear to constrain activation of the NF-κ B-
dependent promoter. In the same stably-transfected
cells, the IL-1β  renilla luciferase did not show either the
rapid decline upon medium replacement, or the increase
in basal activity thereafter (Fig 1C). However, fresh me-
dium did accelerate the response to LPS, and permit the
response to continue rising up to 12 hrs.
Fig 1B shows a comparable time course for the IL-12 pro-
moter. The data for the IL-1β  promoter in this pool of sta-
ble transfectants line were indistinguishable from those
obtained with the ELAM/IL-1 transfectants, and have
been averaged in Fig 1C. Unlike the IL-1 promoter in the
same cells, the response of the IL-12 promoter to LPSBMC Immunology 2001, 2:11 http://www.biomedcentral.com/1471-2172/2/11
was also increased marginally by washing and continued
to increase when the control activation had peaked. Sim-
ilar results were obtained with a population of cells
transfected with an IL-6 firefly luciferase reporter to-
gether with the IL-1 renilla luciferase reporter (data not
shown). These findings suggest that the RAW264 cells
produce a feedback suppressor of LPS response that has
some selectivity for the target promoter being studied.
Because the introduction of fresh medium, or use of
freshly plated-cells creates a rising baseline which is dif-
ficult to interpret, we chose a standard assay procedure
in which the cells were plated late in the afternoon and
stimulated the next day for 8 hrs without changing the
medium. The sensitivity of the assay allowed us to obvi-
ate the effect of accumulated inhibitors following over-
night culture via the use of relatively low starting cell
density (2 ×  105/ml).
Reporter gene lines respond to a wide range of microbial 
agonists with distinct dose response curves
The different indicator cells lines each responded to a
wide diversity of different agonists of bacterial origin in
addition to LPS, including the synthetic bacterial li-
popeptide, PAM3-CSK4 [34], peptidoglycan and bacteri-
al DNA (bDNA) or CpG-containing oligonucleotides.
Figure 2 shows an example using the IL-6 promoter in
combination with the IL-1β  promoter in the same cells.
This study makes several additional points:
1) Activation of expression of both reporter genes was de-
tectable in response to LPS at Ing/ml.
2) The response of both promoters to low doses (1 or 10
ng/ml) of LPS was transient and declined after 10–15
hrs, where the response to higher LPS concentration
(100 ng/ml) was sustained for longer and was still almost
maximal after 24 hrs. Hence, the duration, rather than
the peak magnitude, of the response was most sensitive
to LPS concentration.
3) The different agonists have different relative activities
on the two promoters. In keeping with the previous ob-
servation that IL-1β  is weakly induced by bDNA [8],
bDNA was as effective as LPS at inducing IL-6 promoter
but only half as effective on the IL-1 promoter.
Figure 3 shows dose response curves for LPS, lipopeptide
and bacterial DNA for the IL-12, IL-1 and ELAM-1 pro-
moters. Activity of both the IL-1 and IL-12 promoters
continued to increase up to 500 ng/ml LPS whereas the
activation of ELAM luciferase was detectable at 0.1 ng/
ml and maximally at 10 ng/ml. Given that the ELAM-1
promoter is apparently more sensitive to LPS than other
promoters tested, the rising baseline seen upon addition
of fresh medium (Fig 1) is likely to be due to endotoxin
and/or endotoxin-like activity in serum, which cannot be
completed avoided and which the cells themselves de-
grade with time.
The effects of pretreatment
The main purpose of creating these lines of RAW264
cells is to use them as convenient indicators of interac-
tions amongst signals generated by different microbe-as-
sociated stimuli. We focused upon the IL-12/IL-1 and
ELAM-IL-1 lines, which appear to display the spectrum
Figure 1
Time course of activation of integrated reporter genes in
RAW264 cells. Pooled stable transfectants of RAW264 cells,
with either the ELAM or IL-12 promoter driving firefly luci-
ferase, cotransfected with the IL-1β  promoter driving renilla
luciferase, were cultured overnight as described in Materials
and Methods. Where the cells were washed, the medium
was aspirated, and replaced immediately with warm medium
at time zero. A typical experiment of three is shown. Results
for ELAM and IL12 promoters are the average of duplicates
that differ by less than 10% from the mean. In the case of the
IL-1β  data, the results are the average of 4 datapoints
obtained with the two separate pooled transfectant lines in
the same experiment.
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of contrasting activation patterns. Each line was incubat-
ed overnight (16–18 hrs) with 100 ng/ml LPS, 100 ng/ml
lipopeptide or 10 µg/ml of bacterial DNA, washed twice
with fresh medium, and then re-exposed to a range of ag-
onists. The results are shown In Fig 4. Even after 18 hrs,
luciferase activity was still elevated at least 10-fold in all
cases. In cells washed to remove LPS, the elevated activ-
ity declined by about 70% after 8 hrs, but immediate re-
addition of LPS maintained activity of the ELAM-1, IL-12
and IL-1 promoters. By contrast to the pattern observed
in LPS-stimulated cells deprived of stimulus, ELAM, IL-
12 or IL-1β  promoter luciferase activity stimulated by li-
popeptide did not decline greatly after removal of the
stimulus. bDNA behaved intermediately for all promot-
ers; activity declined 20–60% after removal of the stim-
ulus.
Addition of a different agonist revealed a surprisingly
simple pattern of purely additive responses. This is most
obvious in the case of lipopeptide-treated cells, where
maximal activity was retained despite removal of the pri-
mary agonist. Addition of either LPS or bDNA caused an
almost additive increase in luciferase activity, whereas
addition of peptidoglycan (which probably shares the
TLR2-signalling pathway with lipopeptide) was without
additional effect (data not shown).
Interaction of different agonists with the Toll-like receptor 
pathways
In a separate report, we have examined the ability of
dominant-positive forms of the Toll-like receptors
[TLRs] to mimic actions of the microbial agonists in
macrophages [35]. Activation was achieved by fusing the
extracellular domain of CD4, which promotes spontane-
ous dimerisation, with the intracellular domain of TLRs.
CD4-TLR4 alone was able to activate production of the
cytokine TNF-α , and ELAM luciferase activity. By con-
trast, CD4-TLR2 was active only when transfected in
Figure 2
Time course of activation ofIL-6 and IL-1 promoters in
RAW264 cells and the effect of a range of microbial agonists.
Pooled stable transfectants with the IL-6 promoter driving
firefly luciferase and the IL-6 promoter driving renilla luci-
ferase were incubated overnight then stimulated with the
agents shown for the time indicated prior to assay of luci-
ferase activity. PMA3-CSK was added at 100 ng/ml, peptidog-
lycan at 10 µg/ml and E-coli genomic DNA (bDNA) at 10 µg/
ml. A representative experiment of two is shown. Datapoints
are the average of duplicate wells.
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Figure 3
Comparative dose response curves for activation of IL-12, IL-
1 and ELAM promoters. Pooled stable transfectants of
RAW264 cells, with either the ELAM or IL-12 promoter
driving firefly luciferase, cotransfected with the IL-1β  pro-
moter driving renilla luciferase, were cultured overnight as
described in Materials and Methods. E. coli genomic DNA
(bDNA), LPS or PAM3-CSK lipopeptide (PAM) were added
at the concentrations indicated (LPS and PAM are in ng/ml,
bDNA in µg/ml). After 8 hrs, the cells were harvested for
determination of luciferase activity. Datapoints are the aver-
age of duplicate wells. The experiment is representative of
two, and reiterates the pattern observed in 2 others with dif-
ferences in design.
0
25000
50000
75000
100000
R
L
U
C
o
n
t
r
o
l
0
.
1
L
P
S
1
.
0
 
L
P
S
1
0
 
L
P
S
1
0
0
 
L
P
S
5
0
0
 
L
P
S
1
 
P
A
M
1
0
 
P
A
M
1
0
0
 
P
A
M
1
u
g
 
b
D
N
A
5
 
u
g
 
b
D
N
A
1
0
u
g
 
b
D
N
A
ELAM
IL1
IL12BMC Immunology 2001, 2:11 http://www.biomedcentral.com/1471-2172/2/11
combination with either TLR1 or TLR6. We investigated
whether the active TLRs alone could induce IL-12 luci-
ferase, and whether their actions were additive with their
agonists or, alternatively, produced some kind of toler-
ance.
When the IL-12 luciferase reporter gene was co-trans-
fected into RAW264 cells together with the the CD4-
TLR4 expression vector, reporter gene expression was
strongly induced (Fig 5). By contrast, CD4-TLR2 or CD4-
TLR6 had little effect when added alone. When added in
combination, TLR2 plus TLR6 activated IL-12 luciferase
activity to the same extent as CD-TLR4 added alone. This
pattern of signaling is the same as previously described
for activation of TNF-α  production [35]. Because of the
possible complex effect of stimulatory DNA sequences in
the co-transfected plasmids, we confirmed that the re-
sponse was due to expression of the protein products by
inactivating each signaling domain by mutating a con-
served proline in each TIR domain that corresponds to
the inactivating mutation in TLR4 in the C3H/HeJ
mouse strain, P712H [36,37]. We have previously shown
that mutation of the conserved prolines in TLR2 and
TLR6 similarly inactivates these receptors [34,35]. The
ability of CD4-TLR4 to trans-activate IL-12 promoter ac-
tivity was abolished by the P-H mutation. In fact, the
CD4-TLR4-PH mutant expression plasmid reproducibly
reduced the basal IL-12 promoter activity suggesting that
the mutant receptor may generate a repressive signal. In
the case of TLR2 and TLR6, co-transfection of both P-H
mutant expression plasmids together also suppressed
the basal activity. However, when wild-type TLR2 or 6
was co-transfected with the reciprocal P-H mutant part-
ner, there was a small, but reproducible activation above
the control; even more relative to the level observed
when both partners were P-H mutants. This complex
pattern strongly supports the view that the CD4-TLR2
and CD4-TLR6 heterodimerise in order to signal [35]
and also suggests that the P-H mutation reduces, but
does not completely abolish, the ability of either partner
to contribute some function to an active heterodimer.
RAW264 cells transfected with CD4-TLR plasmids, and
the IL-12 promoter, were incubated overnight, washed
and treated with microbial agonists. The extent of the ac-
tivation by CD4-TLR4 was comparable to that induced
by addition of a maximal dose of LPS (100 ng/ml) to con-
trol cells and LPS did not stimulate further. By contrast,
the effects of both lipopeptide and bacterial DNA were
approximately additive with CD4-TLR4. The converse
experiment gave the expected reciprocal pattern. Li-
popeptide addition to cells transfected with CD-4TLR2/
6 lifted the luciferase activity to the level observed when
the agonist was added to control cells, whereas both LPS
and bacterial DNA effects were almost perfectly additive.
Additive effects of different agonists on inducible cytokine 
production
Both the experiments with stable reporter gene lines,
and the studies of the dominant-active TLRs, suggest
that different Toll-like receptor pathways can operate in-
dependently of each other to induce inflammatory cy-
tokines. To confirm the biological relevance of this
observation, we examined the effect of combined addi-
tion of two such agonists, LPS and CpG DNA. Data in Fig
6 show that combined addition of LPS and bacterial DNA
or the stimulatory CpG oligonucleotide AO-1 actually
produced a more than additive release of TNF-α , IL-6 or
Figure 4
Additive effects of different microbial agonists and lack of evi-
dence of tolerance in reporter gene activation. Pooled stable
transfectants of RAW264 cells, with either the ELAM or IL-
12 promoter driving firefly luciferase, cotransfected with the
IL-1β  promoter driving renilla luciferase, were cultured over-
night for 16–18 hrs with either no addition, LPS (100 ng/ml),
PAM3-CSK lipopeptide (PAM, 100 ng/ml) or E. coli genomic
DNA (bDNA, 10 µg/ml) as indicated on the vertical legend.
The cells were washed by aspirating the medium, replacing it
with warm medium, incubating for 5 minutes and replacing
the medium a second time. The replacement medium con-
tained no additional stimulus, or one of original stimuli as
indicated on the legend to the X-axis, so that a 4 ×  4 matrix
of pretreatment and retreatment was established. After a
further 8 hrs stimulation, the cells were harvested for deter-
mination of luciferase activity. Each datapoint is the average
of duplicate wells. The experiments is representative of two
with identical design. The pattern of restimulation has been
confirmed for LPS, and for the ELAM/IL-1 line in separate
experiments (not shown).
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IL-12 protein from RAW264 cells after 24 hrs. The same
pattern was evident at 8 hrs (not shown). Controls in this
experiment, DNasel-treated DNA and GpC oligonucle-
otide (NAO-1) confirm that the response is, indeed, due
to stimulatory DNA recognition in combination with
LPS. In panel D, the observation is extended to primary
bone marrow-derived macrophages, to provide assur-
ance that this is not a peculiarity of the RAW264 cell line.
Discussion
Contrasting regulation of late response genes in macro-
phages
Macrophages that have been treated with a maximal LPS
dose in vitro fail to respond to restimulation in most ear-
ly response assays including phosphorylation of MAP Ki-
nases, activation of NF-κ B and AP-1 transcription
factors, and induction of a range of cytokine and chem-
okine genes [5,17]. Such responses are transient respons-
es to LPS, and have declined to "almost" basal levels by
the time of restimulation, regardless of whether LPS is
removed. By contrast, there is a family of transcription
factors and target genes that are induced much more
slowly by LPS, and which remain elevated at least 48 hrs
after ligand addition. They include the transcription fac-
tors Ets-2, C/EBP family members and Sp1 [1,38] and
the interferon-regulatory factors [29], the serpin plas-
minogen activator inhibitor-2 and inducible nitric oxide
synthase (iNOS) [23] the cytoskeletal regulators
MARCKS and MacMARCKS [39] and many of the induc-
ible cytokines such as IL-1, IL-6, IL-10 and IL-12 and
other regulators [20,21,31,40–44]. Amongst these sta-
bly-inducible genes is p50NFκ B, a repressor of κ B-de-
pendent transcription, which provides at least one
explanation for suppression of transcription of early re-
sponse genes such as TNF-α  [45].
In this study we have used a novel reporter gene system
to examine how late-responsive genes are regulated. We
show with a number of promoters, including the κ B-de-
pendent ELAM promoter, that the levels of luciferase ac-
tivity increase for at least 8 hrs following addition of
microbial agonists, and are maintained thereafter long
after early events such as nuclear NF-κ B activation and
MAP kinase activation and induction of early response
genes such as TNF-α  has peaked and declined. The ex-
amples we have shown, IL-6, IL-12 and ELAM are only a
subset of the promoter combinations we have tested suc-
cessfully. At least for IL-1β  and iNOS, the time course of
luciferase activation is consistent with the time course of
transcriptional activation of the corresponding gene
measured previously using nuclear run-on transcription
assays in the same cells [23].
The key observation in the present paper is that luci-
ferase activity declines upon removal of the agonists LPS
and bacterial DNA, and this decline can be prevented by
immediate re-addition of the agonists. The observation
that this is not readily apparent for the agonist PAM3-
CSK4 may reflect something fundamentally different
about its signaling pathway, or may simply reflect a re-
duced ability of the cell to degrade or detoxify residual
amounts of this ligand. The implications of the declining
signals seen after ligand removal are two-fold. Firstly the
cells are not LPS-unresponsive, and secondly mainte-
nance of the induced luciferase requires continuous
stimulation by LPS (or lipopeptide or bacterial DNA as
the case may be). In keeping with this interpretation, the
response of the IL-1, IL-6 and IL-12 promoters to sub-
maximal doses of LPS peaked and declined earlier (Figs
2,3) presumably because the cells consume the ligand,
and the response then declines. A useful analogy can be
drawn with the activation of the CSF-1 receptor in mac-
rophages. The addition of CSF-1 to cells previously
starved of ligand causes a rapid activation of signalling
pathways leading to MAP kinase activation, PI-3-kinase,
Figure 5
Combined effects of constitutively active toll-like receptors
and added agonists. RAW264 cells were transiently co-trans-
fected with the IL-12 promoter luciferase reporter genes and
expression plasmids encoding wild-type and mutated (indi-
cated by an asterisk) forms of the CD4/TLR chimaeric recep-
tors as indicated either alone for TLR4 or in combination for
TLR2 and 6. The experiment is described in detail in Materi-
als and Methods. After overnight incubation, the cells were
treated with either LPS [100 ng/ml], PAM3-CSK lipopeptide
(100 ng/ml) or E-coli genomic DNA (10 µg/ml) as indicated.
Each datapoint is the average of duplicate wells. The same
pattern was observed in three separate experiments. The
major variation between experiments was in the effect of the
vector alone on basal reporter gene activity.
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induction of AP-1 and Ets-2 transcription factors, and ul-
timately transcriptional activation of specific target
genes such as the urokinase plasminogen activator gene
(uPA) [46]. It is a sequential cascade, since Ets-2 must be
induced before it can be phosphorylated by activated
MAP kinase [46]. Ets-2 phosphorylation is also induced
by LPS [38] and probably relates to the ability of LPS to
prevent apoptosis in macrophages [9]. In stimulated
cells, the CSF-1R binds ligand, and is rapidly internalised
and degraded. The CSF-1R mRNA (encoded by the c-fms
proto-oncogene) is substantially down-modulated (an-
other response mimicked by LPS; [9]). Yet, uPA mRNA
is maintained for as long as CSF-1 is present; removal of
CSF-1 leads to rapid degradation of uPA mRNA in a man-
ner that is blocked by inhibitors of protein or RNA syn-
thesis [47]. The implication is that after the initial
signalling pulse, the cells must continue to recognise and
respond to ligand in a quite distinct manner. Indeed, al-
though the steady level of CSF-1 receptor is low, activity
can be discerned from the continued degradation of the
ligand by the cells [48]. In the case of LPS, recent availa-
bility of TLR4 antibody supports a similar mechanism.
The initial recognition of LPS was shown to lead to rapid
down-modulation of TLR4 from the cell surface and re-
duced expression of TLR4 mRNA [5].
Although we have questioned the nature of LPS tolerance
in macrophages treated in vitro, the data we have ob-
tained actually provide a plausible mechanism for LPS
tolerance in vivo. The double reporter system enabled us
to confirm and extend an earlier finding showing that
early LPS responses, such as induction of TNF-α  and NF-
κ B-dependent transcriptional activation (e.g. part of the
ELAM-1 activation and the earlier HIV-1-LTR respons-
es) require at least 10-fold lower concentration of LPS
than later responses. We suggest that early responses
such as TNF-α  induction are activated solely in response
to an initial bolus of LPS or other agonist interacting with
receptor, a response that is truly concentration depend-
ent. By contrast, activation of late response genes, which
requires the continued presence of the ligand, depends
upon the amount of ligand available to each cell. Agonist
availability is a function of the concentration of the cells
and the rate at which they deplete the medium of agonist.
By analogy, that pattern was demonstrated with CSF-1,
where the dose response curve for induction of uPA and
cell growth is a function of cell concentration [49]. In
simple terms, late response genes require more agonist
because the cells must receive a continuous supply for
the duration of the biological response. When macro-
phages respond to local LPS exposure in vivo, where the
agonist is rapidly cleared or diluted by body fluids, or
they have engulfed a single microorganism, they give a
pulse of cytokines and chemokines that activates the
acute phase and causes local inflammation. Conversely,
continued exposure of the cells to the stimulus is indica-
tive of the failure of initial defence, and the need to max-
imally activate the host, including the acquired immune
system. When LPS is not cleared, the macrophages pro-
gressively induce more and more of the cytokine genes in
a manner that is a linear function of the duration of ex-
posure.
The additive nature of signalling pathways in macrophages
As discussed in the introduction, each of the three broad
classes of agonist studied here apparently requires the
Figure 6
Combined effects of LPS and bacterial DNA on pro-inflam-
matory cytokine production Panels A-C. RAW264 cells were
stimulated for 24 h with medium control, LPS [100 ng/ml],
stimulatory CpG oligonucleotide AO-1 (3 µM), non-stimula-
tory GpC oligonucleotide NAO-1 (3 µM),  E. coli DNA
(bDNA, 5 µg/ml), DNase I-treated bDNA (5 µg/ml) or com-
binations as indicated. Cell supernatants were harvested and
IL-6 (Panel A), IL-12 (Panel B] and TNF-β  (Panel C) levels
were estimated by ELISA. Data are mean of triplicates ± SD
and similar results were obtained in 3 independent experi-
ments. Panel D. Bone marrow-derived primary macrophages
were stimulated with medium control, LPS (100 ng/ml), AO-
1 (3 µM), NAO-1 (3 µM), E. coli DNA (bDNA, 5 µg/ml),
DNase I-treated E. coli DNA (5 µg/ml), or combinations as
indicated. After 24 h, cell supernatants were harvested and
IL-12 levels in supernatants were estimated by ELISA. Data
(mean of triplicates ± SD) are representative of 4 independ-
ent experiments.
0
1000
2000
3000
4000
I
L
-
6
 
(
p
g
/
m
l
)
0
2000
4000
6000
8000
I
L
-
1
2
 
(
p
g
/
m
l
)
A
B
0
1000
2000
3000
4000
5000
C
O
N
L
P
S
A
O
-
1
N
A
O
-
1
b
D
N
A
b
D
N
A
 
D
N
a
s
e
d
L
P
S
+
A
O
-
1
L
P
S
+
N
A
O
-
1
L
P
S
+
b
D
N
A
L
P
S
+
b
D
N
A
 
D
N
a
s
e
d
treatment
C
T
N
F
 
(
p
g
/
m
l
)
0
10000
20000
30000
40000
C
O
N
L
P
S
A
O
-
1
N
A
O
-
1
b
D
N
A
b
 
D
N
A
 
D
N
a
s
e
d
L
P
S
+
A
O
-
1
L
P
S
+
N
A
O
-
1
L
P
S
+
b
D
N
A
L
P
S
+
 
b
D
N
A
 
D
N
a
s
e
d
treatment
I
L
-
1
2
 
(
p
g
/
m
l
) DBMC Immunology 2001, 2:11 http://www.biomedcentral.com/1471-2172/2/11
adaptor protein MyD88 for maximal activity and acts to
induce NF-κ B. Despite the shared pathways, maximal
activation of the TLR4 pathway, with either CD4-TLR4
or LPS, did not prevent an additive response to the
TLR2/6 agonists lipopeptide and peptidoglycan. Con-
versely, maximal activation of the TLR2/6 pathway with
lipopeptide did not block an additive response to LPS.
Bacterial DNA effects were additive with either of these
classes of agonist. There are relatively few reports on the
effects of the combined addition of microbial agonists. In
recent studies, two groups studying early gene responses
have reported "cross-tolerance" of TLR2 and TLR4-me-
diated responses [25,26]. In other studies, responses
were at least additive. For example, bacterial DNA and
LPS were reported to exert more than additive effects on
the iNOS gene in macrophages [50]. We have now shown
that the effects on cytokines such as TNF-α , IL-6 and IL-
12 are also more than additive (Fig 6).
There may be good reason for the innate immune system
to retain the ability to respond maximally to different
classes of infectious challenge. The global responses to
TLR4 and TLR2/6 activation may not be identical (e.g.
gram-positive organisms may not induce interferon-β
[51]), and the innate immune system may quite com-
monly respond to multiple classes of challenge in a
mixed infection. For example, TLR4-deficient mice dis-
play reduced pathology when challenged with mixed in-
fections [52].
From a signaling perspective, the simplest explanation is
that the response to any agonist is limited solely or pri-
marily by the availability of surface receptor, and all the
downstream effectors are available in excess. Based upon
the ability of LPS to repress TLR4 mRNA expression [5],
CD4-TLR4 and CD4-TLR2/6 probably act to repress sur-
face expression of the corresponding full-length recep-
tors, thereby preventing super-activation. An alternative
is that each pathway associates with a separate function-
al pool of signalling molecules that need not be identical.
If this were the case, one might expect that overexpres-
sion of CD4-TLR4 would result in the utilization of more
downstream signaling molecules than full activation of
endogenous TLR4 could assemble. This appears not to
be so since maximal activation by LPS and CD4-TLR4
were remarkably similar. The fact that bacterial DNA ac-
tion is additive with either CD4-chimaera, or with LPS or
lipopeptide, implies that recognition does not absolutely
require either TLR4 or TLR2/6. In keeping with this
view, macrophages and B cells from knockout mice defi-
cient in either TLR2 or TLR4 respond normally to bacte-
rial DNA, whereas the recent knockout of TLR9 is
selectively defective in DNA signalling [10].
Conclusion
We have shown that macrophages exposed to LPS or oth-
er microbial agonists do not become refractory to stimu-
lation. Rather, they have entered a new steady state
which requires continued stimulation and in which other
agonists can generate a further amplification of the re-
sponse. It may be a characteristic of the "activated"
steady state that genes activated during the transition
phase from the "inactive" state cannot be reactivated. We
have presented an analogy with growth factor responses,
where macrophage cells do not respond to CSF-1 with re-
activation of the Ets/APl pathway unless they have been
starved of ligand and maximal cell surface receptor has
re-appeared. This is not referred to as CSF-1 tolerance,
and the phenomenon that has been studied as LPS toler-
ance  in vitro is, based upon our findings, equivalent.
This state of tolerance is, in reality, a state of sustained
and continued activation.
Materials and Methods
Promoter constructs
The human interleukin 1B promoter clones into the luci-
ferase vector pGL3 was a gift from Dr. Matt Fenton [53].
We subcloned the promoter fragment into the corre-
sponding sites of the Promega renilla luciferase vector.
The IL-6 luciferase reporter (pIL6-luc651) was provided
by Dr. Oliver Eickelberg [54]. The IL-12 reporter was
constructed by us. The murine IL-12 p40 promoter re-
gion from -349 to +56 [55] was generated by PCR and
cloned into the pGL2-basic KpnI/XhoI site. The ELAM
luciferase reporter is as previously described [33].
Transfection
5 ×  l06 RAW264 cells were transfected by electropora-
tion as described previously [56]. To avoid phenotypic
drift in cell culture [23], all experiments were carried out
using RAW264 cells that had been recently obtained
from the American Type Culture collection, expanded
immediately, and then frozen in aliquots. Cells were
maintained in culture for no more than 4–6 weeks. All
cell culture, including the electroporation procedure,
was carried out in RPMI1640 medium with 10 mM
HEPES (pH7.4) and 10% fetal bovine serum. The inclu-
sion of HEPES is a departure from previous studies and
appears to increase survival and transfection efficiency.
In each transfection, we added 10 µg of the desired firefly
luciferase reporter gene, 10 µg of the IL-1β  promoter-re-
nilla luciferase plasmid and 2 µg of the selective marker
plasmid pNeoTak which also directs expression of the
Tet represser [34]. In this system, only the Neo resist-
ance is relevant, but the Tet represser could be used sub-
sequently for studies using inducible modifier cassettes.
After transfection, the cells were placed in a 100 mm
square bacteriological petri dish (Sterilin) with approxi-
mately 25 ml of medium. Following overnight incuba-BMC Immunology 2001, 2:11 http://www.biomedcentral.com/1471-2172/2/11
tion, most viable cells adhere weakly. The medium was
changed, and G418 (200 µg/ml) was added. The cells
were left in culture with one change of medium to re-
move dying cells around day 4–5. By day 7–10, several
hundred individual foci of stably transfected cells were
evident in each dish. These were removed by washing of
the surface using a syringe with an 18 g needle (the cells
are weakly adherent to bacteriological plastic), expanded
and frozen in aliquots for future experiments.
For studies of the dominant-positive TLR receptors,
RAW264 cells were transiently transfected by electropo-
ration using 2 µg of the desired expression plasmid en-
coding the CD4-TLR chimaeric receptor described in
Ozinsky et al. [35] together with 10 µg of the IL12 pro-
moter luciferase vector. Cells from one transfection were
plated into 1 ml of medium in 24 wells for 4–6 hours, the
medium was changed to remove dead cells, and the cells
were then incubated overnight. The desired agonist was
added to the cells without further change of medium, and
the cells were harvested 8 hrs later for luciferase deter-
mination.
Luciferase assays
For analyses of the response to various agonists, 2 ×  105
of the transfected RAW264 cells were placed in 1 ml of
medium in 24 well tissue culture plates and incubated
overnight. In some experiments, the medium was re-
placed with prewarmed medium. Agonist at the desired
final concentration was added in a small volume, and the
cells were incubated for the desired time at 37°C. Cells
were harvested and analysed simultaneously for firefly
and renilla luciferase activity using the Promega Dual
Luciferase reporter assay reagents. In each experiment,
duplicate wells were tested; results generally differed by
less than 10% of the mean.
Analysis of cytokine production by RAW264 cells and pri-
mary macrophages
Bone marrow-derived macrophages (BMM) were de-
rived from the femurs of adult BALB/c mice (Harlan Ol-
ac, Bicester, UK) by plating bone marrow cells in fresh
medium containing 10% L929 medium as a source of
CSF-1 on 10 cm bacteriological plastic plates (Bibby Ster-
ilin, Staffordshire, UK) for 7 days in a 37°C incubator
containing 5% CO2. LPS from Salmonella minnesota
(Sigma, Poole, UK) was used at a final concentration of
100 ng/ml in all cell culture experiments and E. coli DNA
(Sigma) was used at a final concentration of 5 µg/ml in
cell culture. For control experiments, E. coli DNA was di-
gested to completion at 37°C with DNase I (Roche, Indi-
anapolis, IN) in 10 mM Tris-Cl, 10 mM MgCl2 and 1 mM
DTT. Phosphodiester oligodeoxynucleotides (Sigma-
Genosys, Poole, UK) were used at a final concentration of
3 µM in cell culture. Oligodeoxynucleotides used were
activating oligonucleotide-1 (AO-1; 5'-GCT CAT GAC
GTT CCT GAT GCT G-3') and nonactivating oligonucle-
otide (NAO-1; 5'-GCT CAT GAG CTT CCT GAT GCT G-3',
[9]). RAW264 cells were plated out at 2 ×  105 cells per
well and BMM at 5 ×  105 cells per well in 1 ml complete
medium (in the case of BMM, medium contained 10%
L929 medium) in 24 well plates on the evening before
the experiment. The following day cells were stimulated
for 24 h as outlined in the figure legends, supernatants
were collected and IL-6, IL-12 and TNF-α  levels were de-
termined by ELISA using paired antibodies (Pharmin-
gen, San Diego, CA).
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